ERBB2 and breast cancer: Darkfield microscopy and cell binding assays (Fig. 6b) revealed that DRT radiation nanomedicines were bound by MDA-MB-231/H2N cells expressing both EGFR and HER2, while SRT forms were bound only by BC cells that displayed either EGFR or HER2.